NCT06684743View on ClinicalTrials.gov

Vaccine Effectiveness of a Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing RSV Hospitalizations in Older Adults

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

130,000

Participants

Timeline

Start Date

November 18, 2024

Primary Completion Date

May 31, 2027

Study Completion Date

August 31, 2027

Conditions
RSV
Interventions
BIOLOGICAL

RSV prefusion F protein-based vaccine

For this arm, the RSV prefusion F protein-based vaccine Abrysvo® will be used

Trial Locations (2)

2860

Danske Lægers Vaccinations Service, Søborg

2900

Center for Translational Cardiology and Pragmatic Randomized Trials Department of Cardiology Copenhagen University Hospital - Herlev and Gentofte, Copenhagen

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Tor Biering-Sørensen

OTHER